Howe & Rusling Inc. Purchases 4,351 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Howe & Rusling Inc. has increased its holdings in Edwards Lifesciences Corporation by 5.6% by purchasing an additional 4,351 shares, bringing their total holdings to 81,914 shares valued at approximately $5.94 million.
• Insider transactions included VP Daniel J. Lippis selling 4,114 shares at $79.46, reducing his ownership by 15.75%, while insider Larry L. Wood sold 8,950 shares at $75.23.
• Edwards Lifesciences reported earnings of $0.67 EPS, surpassing estimates, with revenues of $1.53 billion for the latest quarter, which was an 11.9% increase year-over-year.

Howe & Rusling Inc. increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,914 shares of the medical research company's stock after purchasing an additional 4,351 shares during the period. Howe & Rusling Inc.'s holdings in Edwards Lifesciences were worth $5,937,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the first quarter valued at $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences during the fourth quarter valued at $27,000. SouthState Corp purchased a new position in Edwards Lifesciences during the first quarter valued at $27,000. Global X Japan Co. Ltd. grew its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after acquiring an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC grew its stake in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after acquiring an additional 205 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,014 shares of company stock valued at $1,698,844. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $78.01 on Friday. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The stock has a market capitalization of $45.80 billion, a P/E ratio of 11.22, a PEG ratio of 3.78 and a beta of 1.07. The firm has a fifty day simple moving average of $78.91 and a two-hundred day simple moving average of $75.35. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the company earned $0.70 EPS. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of several research analyst reports. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a research note on Tuesday, July 29th. Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Finally, Citigroup reaffirmed a "buy" rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $86.26.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.